CE

Cellbion Co., Ltd

Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.

308430 | KO

Overview

Corporate Details

ISIN(s):
KR7308430008
LEI:
Country:
South Korea
Address:
서울특별시 종로구 대학로 103 서울대학교 암연구소 6층, 종로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellbion Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of radiopharmaceuticals. The company focuses on advancing Radioligand Therapy (RLT) and antibody-based treatments to address unmet medical needs, particularly in oncology. Its pipeline includes diagnostic imaging agents for PET CT and therapeutic drugs, with a key program targeting Prostate-Specific Membrane Antigen (PSMA) for the diagnosis and therapy of prostate cancer. Cellbion operates a GMP-certified facility for the production of liquid and lyophilized injectable products, supporting both clinical trials and commercial supply.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) …
Korean 12.6 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-04 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (표준요법에 실패한 전이성 거세저항성 전립선암 환자에서 Lu177DGUL의 국내 …
Korean 16.8 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-23 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGU…
Korean 9.0 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.3 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 460.8 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 18.9 KB
2025-03-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 119.1 KB
2025-01-31 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.5 KB

Automate Your Workflow. Get a real-time feed of all Cellbion Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellbion Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellbion Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.